Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 15/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | ESRRG | P62508 | 3/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180762 | 0.89 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1181010 | 0.88 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1180118 | 0.84 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20764241 | 0.84 | HSD17B1 (0.72) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1028270 | 0.84 | ESR2 (0.72) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1180468 | 0.82 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1180426 | 0.82 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1180589 | 0.81 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1180066 | 0.78 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28527720 | 0.76 | HSD17B1 (0.62) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | UNIVERSITAT DES SAARLANDES (DE) | 2011-02-24 | — | — | US | claimed |
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | UNIVERSITAT DES SAARLANDES (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | UNIVERSITAT DES SAARLANDES (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | UNIVERSITAT DES SAARLANDES (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009027346-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046147-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES | HSD17B1, HSD17B11, HSD17B2 | HSD17B1 1/4885HSD17B2 3/4885CYP3A4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.